Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: Planned analyses of a randomized trial

Integrated Blood Pressure Control

Volumn 6, Issue , 2013, Pages

  Zhu, Dingliang ^a   Bays, Harold ^b   Gao, Pingjin ^a   Mattheus, Michaela ^c   Voelker, Birgit ^c   Ruilope, Luis M ^d  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Age; Gender; Grade 2 and 3 hypertension; Hydrochlorothiazide; Race; Telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE; TELMISARTAN;

AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHMA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENDER; HUMAN; HYPERTENSION; INSECT BITE; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; MYALGIA; OROPHARYNX PAIN; POLLAKISURIA; RACE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; URIC ACID BLOOD LEVEL; VULVOVAGINAL DISEASE;

EID: 84875969484     PISSN: None     EISSN: 11787104     Source Type: Journal    
DOI: 10.2147/IBPC.S33104     Document Type: Article

References (27)

1. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13(3): 146-154.
2. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499-2506.
3. Franklin SS, Neutel JM. Initial combination therapy for rapid and effective control of moderate and severe hypertension. J Hum Hypertens. 2009;23(1):4-11.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and t{stroke}reatment of high blood pressure. Hypertension. 2003;42(6): 1206-1252.
5. Mancia G, De BG, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
6. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566-572.
7. Bangalore S, Ley L. Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert Opin Pharmacother. 2012;13(3):345-355.
8. Plosker GL, White WB. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs. 2008;68(13):1877-1899.
9. Zhu DL, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of initial therapy with single-pill combination t{stroke}elmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. Clin Ther. 2012;34(7):1613-1624.
10. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002;61(3):1047-1055.
11. Neutel JM. Long-term blood pressure control: what can we do? Postgrad Med. 2011;123(1):88-93.
12. Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118(13): 1383-1393.
13. Gupta AK. Racial differences in response to antihypertensive therapy: does one size fits all? Int J Prev Med. 2010;1(4):217-219.
14. Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006; 98(4):618-626.
15. Cushman WC, Neutel JM, Saunders E, et al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008;17(1):27-36.
16. Ofili EO, Cable G, Neutel JM, Saunders E. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. J Womens Health (Larchmt). 2008;17(6): 931-938.
17. Nash DT, Crikelair N, Zappe D. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies. Curr Med Res Opin. 2008; 24(9):2617-2626.
18. White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens. 2009;23(12): 817-825.
19. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensinaldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3): 531-548.
20. Koh KK, Quon MJ, Han SH, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010;140(1):73-81.
21. Srivastava TN, Young DB. Impairment of cardiac function by moderate potassium depletion. J Card Fail. 1995;1(3):195-200.
22. Franse LV, Pahor M, Di BM, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000; 35(5):1025-1030.
23. Hwang KS, Kim GH. Thiazide-induced hyponatremia. Electrolyte Blood Press. 2010;8(1):51-57.
24. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7): 741-751.
25. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol. 1985;121(1):11-18.
26. Sowers JR, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010;28(8):1761-1769.
27. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metabol Syndr. 2010;2(1):44-54.